BIOMAT Database Logo BIOMAT Database Logo

Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals. 1988

K J Weinhold, and H K Lyerly, and T J Matthews, and D S Tyler, and P M Ahearne, and K C Stine, and A J Langlois, and D T Durack, and D P Bolognesi
Department of Surgery, Duke University Medical Center, Durham, North Carolina.

Forty-one patients seropositive for human immunodeficiency virus type 1 (HIV-1) were assessed for cell-mediated cytotoxicity (CMC) against autologous target cells bearing the major envelope glycoprotein of HIV-1, gp120. Effector lymphocytes from over 85% of seropositive patients showed CMC specific for gp120-coated targets, whereas seronegative individuals had no detectable CMC. As a group, symptomless individuals had the highest levels of CMC; patients with AIDS-related complex and AIDS showed progressively diminished reactivity. The gp120-specific CMC was mediated by a population of non-T-cell effectors phenotypically resembling NK/K cells. Cytolysis was not restricted by major histocompatibility complex determinants, as shown by killing of heterologous gp120-adsorbed targets and of HIV-1-infected cell-lines. Gp120-specific CMC was highly augmented in the presence of interleukin 2, so it may be possible to develop therapeutic strategies aimed at destruction of virus-producing cell reservoirs in infected individuals through stimulation of HIV-specific host CMC.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D000920 Antibody-Dependent Cell Cytotoxicity The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. ADCC,Cytotoxicity, Antibody-Dependent Cell,Cell Cytoxicity, Antibody-Dependent,Antibody Dependent Cell Cytotoxicity,Antibody-Dependent Cell Cytotoxicities,Antibody-Dependent Cell Cytoxicities,Antibody-Dependent Cell Cytoxicity,Cell Cytotoxicities, Antibody-Dependent,Cell Cytotoxicity, Antibody-Dependent,Cell Cytoxicities, Antibody-Dependent,Cell Cytoxicity, Antibody Dependent,Cytotoxicities, Antibody-Dependent Cell,Cytotoxicity, Antibody Dependent Cell,Cytoxicities, Antibody-Dependent Cell,Cytoxicity, Antibody-Dependent Cell
D012191 Retroviridae Proteins Proteins from the family Retroviridae. The most frequently encountered member of this family is the Rous sarcoma virus protein. Leukovirus Proteins,Retrovirus Proteins,Proteins, Leukovirus,Proteins, Retroviridae,Proteins, Retrovirus

Related Publications

K J Weinhold, and H K Lyerly, and T J Matthews, and D S Tyler, and P M Ahearne, and K C Stine, and A J Langlois, and D T Durack, and D P Bolognesi
HIV-1 group N among HIV-1-seropositive individuals in Cameroon.
November 2000, AIDS (London, England),
K J Weinhold, and H K Lyerly, and T J Matthews, and D S Tyler, and P M Ahearne, and K C Stine, and A J Langlois, and D T Durack, and D P Bolognesi
Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial.
January 1999, Clinical immunology (Orlando, Fla.),
K J Weinhold, and H K Lyerly, and T J Matthews, and D S Tyler, and P M Ahearne, and K C Stine, and A J Langlois, and D T Durack, and D P Bolognesi
Internal-image anti-idiotype HIV-1gp120 antibody in human immunodeficiency virus 1 (HIV-1)-seropositive individuals with thrombocytopenia.
February 1992, Proceedings of the National Academy of Sciences of the United States of America,
K J Weinhold, and H K Lyerly, and T J Matthews, and D S Tyler, and P M Ahearne, and K C Stine, and A J Langlois, and D T Durack, and D P Bolognesi
IgG antibodies to HIV-1 in urine of HIV-1 seropositive individuals.
April 1988, Lancet (London, England),
K J Weinhold, and H K Lyerly, and T J Matthews, and D S Tyler, and P M Ahearne, and K C Stine, and A J Langlois, and D T Durack, and D P Bolognesi
Anti-STLV-IIImac reactivity in HIV seropositive individuals in Sweden.
August 1986, Lancet (London, England),
K J Weinhold, and H K Lyerly, and T J Matthews, and D S Tyler, and P M Ahearne, and K C Stine, and A J Langlois, and D T Durack, and D P Bolognesi
HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals.
November 1997, Nature medicine,
K J Weinhold, and H K Lyerly, and T J Matthews, and D S Tyler, and P M Ahearne, and K C Stine, and A J Langlois, and D T Durack, and D P Bolognesi
Pursuit eye movement dysfunction in HIV-1 seropositive individuals.
December 1991, Journal of psychiatry & neuroscience : JPN,
K J Weinhold, and H K Lyerly, and T J Matthews, and D S Tyler, and P M Ahearne, and K C Stine, and A J Langlois, and D T Durack, and D P Bolognesi
HIV-1 neutralizing antibodies in urine from seropositive individuals.
January 1990, Journal of acquired immune deficiency syndromes,
K J Weinhold, and H K Lyerly, and T J Matthews, and D S Tyler, and P M Ahearne, and K C Stine, and A J Langlois, and D T Durack, and D P Bolognesi
Detection of HIV-1 RNA in heparinized plasma of HIV-1 seropositive individuals.
February 1992, Journal of virological methods,
K J Weinhold, and H K Lyerly, and T J Matthews, and D S Tyler, and P M Ahearne, and K C Stine, and A J Langlois, and D T Durack, and D P Bolognesi
Reducing HIV-1 transmission through prevention strategies targeting HIV-1-seropositive individuals.
February 2006, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!